04:45 PM EST, 11/05/2024 (MT Newswires) -- Exact Sciences ( EXAS ) reported a Q3 loss late Tuesday of $0.21 per diluted share, compared with breakeven a year earlier.

Analysts polled by Capital IQ expected a loss of $0.18.

Revenue for the quarter that ended Sept. 30 was $708.7 million, up from $628.3 million a year earlier.

Analysts surveyed by Capital IQ expected $717 million.

The company expects full-year 2024 revenue of $2.73 billion to $2.75 billion, compared with its prior projections of $2.81 billion to $2.85 billion. Analysts polled by Capital IQ expect $2.83 billion.

Shares of Exact Sciences ( EXAS ) traded 28% lower in after-hours activity.